• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,664.21 -999.79
( -1.29%)
Global Indices
Nasdaq
49,249.13 -82.20
(-0.17%)
Dow Jones
7,185.72 56.32
(0.79%)
Hang Seng
59,744.07 603.84
(1.02%)
Nikkei 225
10,387.94 -69.07
(-0.66%)
Forex
USD-INR
94.05 0.29
(0.31%)
EUR-INR
109.99 0.01
(0.01%)
GBP-INR
126.84 0.17
(0.14%)
JPY-INR
0.59 0.00
(0.16%)

EQUITY - MARKET SCREENER

Sun Pharmaceutical Industries Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524715
INE044A01036
99.2482659
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
SUNPHARMA
89.06
388680.27
EPS(TTM)
Face Value()
Div & Yield %
18.19
1
0.99
 

MCX rallies after easing additional margins on gold, silver futures
Feb 19,2026
In a circular, MCX stated that additional margin of 3% levied in Gold Futures (all contracts of all variants) and 7% levied in Silver Futures (all contracts of all variants) shall be withdrawn with effect from Thursday, February 19th, 2026.

Earlier on 5 February 2026, the exchange had imposed additional margin to mitigate systematic risk. It levied an extra 4.5% margin on silver futures (all variants) and 1% on gold futures (all variants) effective 5 February 2026 (beginning of day). Subsequently, from 6 February 2026 (beginning of day), a further 2.5% margin was imposed on silver futures and 2% on gold futures contracts.

MCX is India's largest commodity derivatives exchange, with around 98% market share in commodity futures. It offers trading in a diverse range of commodities, spanning multiple segments including bullion, energy, metals and agri commodities, as well as sectoral commodity indices.

The company reported 150.63% year-on-year (YoY) surge in consolidated net profit to Rs 401.12 crore in Q3 FY26, compared with Rs 160.04 crore in Q3 FY25. Income from operations jumped 120.85% YoY to Rs 665.62 crore for the quarter ended 31 December 2025.